Abstract
Abstract The discovery of cancer cells' dependency on the self-cannibalization program autophagy has spawned the investigation of its efficacy as a therapeutic target. However, the use of lysomotropic agents to inhibit autophagy as single-agent therapeutics has proven less than optimal. Recent investigations into the design of sequential treatment strategies targeting pathways preferentially used by cancer cells have shown promise. This novel spin on personalized medicine seeks to exploit the kinetics and mechanisms by which cancer cells become dependent on proliferation and survival pathways. Oncogenic KRAS-driven non-small cell lung cancer (NSCLC) is known to depend on mTORC1-driven growth and autophagy for survival; such autophagy addiction is beneficial to cancer cells, as it eliminates the need for exogenous nutrient supplies. We aim to elucidate the mechanism and kinetics of autophagy addiction in NSCLC, in order to design sequential treatment strategies against this disease. Citation Format: Abigail R. Solitro, Jeffrey P. MacKeigan. Kicking the addictions: Therapeutic strategies for NSCLC. [abstract]. In: Proceedings of the AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; Sep 14-17, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(7 Suppl):Abstract nr B08.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
